Anjali Pandey, Ph.D.
EVP of Small Molecule Drug Discovery Research & Development
Dr. Anjali Pandey serves as Executive Vice President of Small Molecule Drug Discovery Research & Development for Navire Pharma and for BridgeBio, Navire’s parent company. Prior to Navire Pharma, she was Senior Vice President Medicinal Chemistry & Chemical Development at Portola Pharmaceuticals from 2003-2018. Prior to Portola, she held senior director positions at Millennium Pharmaceuticals and COR Therapeutics. Dr. Pandey has more than 25 years of hands-on involvement and experience in all stages of drug discovery and development, from initial lead identification to Phase 3 clinical trial, NDA submission, FDA approval, and launch of Portola Pharmaceuticals’ first FDA approved product Bevyxxa™ (Betrixaban). She has published over 40 scientific publications and is co-inventor on 60 issued U.S. patents and 40 U.S. patent applications. Dr. Pandey holds a Ph.D. in synthetic organic chemistry from Southern Illinois University, Carbondale and a M.S. in chemistry from the Indian Institute of Technology, Kanpur.